Related Experiment Video
Updated: Nov 25, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
A review of current progress in triple-negative breast cancer therapy
Meiying Shen1, Huawen Pan2, Yuxia Chen1
1Department of Mammary Gland, Maoming People's Hospital, Maoming, 525000, China.
Abstract:
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic targets. Researchers are aiming to advance TNBC treatment worldwide. In the past 2-3 years, more positive results have emerged in the clinical research on TNBC treatment. Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC. Although neoadjuvant therapy has focused on combinations of systemic agents to optimize pathologically complete response, metastatic TNBC still has a poor prognosis. Innovative multidrug combination systemic therapies based on neoadjuvants and adjuvants have led to significant improvements in outcomes, particularly over the past decade.
Insights
Triple-negative breast cancer (TNBC) treatment is advancing with new drugs like PARP inhibitors and immunotherapy. Recent research shows improved outcomes for TNBC patients, especially with combination therapies.
Area of Science:
- Oncology
- Medical Research
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with high drug resistance and poor prognosis.
- Limited targeted therapies exist for TNBC, driving research for new treatment strategies.
Purpose of the Study:
- To review recent advancements in TNBC treatment.
- To highlight emerging therapeutic targets and combination strategies for TNBC.
Main Methods:
- Review of clinical research and drug approvals in TNBC treatment over the past 2-3 years.
- Analysis of outcomes for approved therapies including PARP inhibitors and immunotherapy.
Main Results:
- Approval of PARP inhibitors (olaparib, talazoparib) for germline BRCA mutation-associated breast cancer (gBRCAm-BC).
- Approval of atezolizumab plus nab-paclitaxel for PD-L1+ advanced TNBC.
- Significant improvements in outcomes observed with innovative multidrug combination therapies.
Conclusions:
- Recent advances have led to approved therapies benefiting TNBC patients.
- Combination systemic therapies, including neoadjuvants and adjuvants, show promise for improving outcomes.
- Further research into innovative multidrug combinations is crucial for advancing TNBC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...